凝血因子VIII治疗强度与非重型血友病A患者抑制物发生:INSIGHT病例对照研究结果
该国际巢式病例对照研究从2709例非重型血友病A患者中选取75例抑制物患者和223例对照,发现手术治疗与高剂量因子VIII浓缩物均与抑制物风险升高相关,而连续5或10个暴露日的峰值治疗未增加风险。作者建议未来医生应更审慎地评估因子VIII剂量和择期手术的依据。
要点
- 手术与抑制物风险升高相关(aOR 4.2,95%CI 1.7-10.3)。
- 平均高剂量因子VIII(>45 IU/kg/暴露日)与抑制物风险升高相关(aOR 7.5,95%CI 1.6-35.6)。
- 连续5或10个暴露日的峰值治疗未增加抑制物风险。
核心结论
- 研究结果提示高剂量因子VIII治疗和手术增加非重型血友病A患者抑制物发生风险。
- 结合非重型血友病A患者终身存在抑制物发生风险的认识,作者建议未来医生应更审慎地评估因子VIII剂量和择期手术的依据。
研究设计与样本
- 国际巢式病例对照研究,从INSIGHT队列研究的2709例非重型血友病A患者(FVIII:C 2-40%)中选取75例抑制物患者(病例)和223例对照。
- 病例与对照按出生日期和因子VIII浓缩物累积暴露日数匹配。
- 采用条件logistic回归计算未调整和调整比值比(aOR),后者针对预先指定的混杂因素进行调整。
主要发现
- 连续5个暴露日的峰值治疗未增加抑制物风险(aOR 1.0,95%CI 0.4-2.5)。
- 连续10个暴露日的峰值治疗未增加抑制物风险(aOR 1.8,95%CI 0.6-5.5)。
- 手术治疗与抑制物风险升高相关(aOR 4.2,95%CI 1.7-10.3)。
- 因子VIII浓缩物平均高剂量(>45 IU/kg/暴露日)与抑制物风险升高相关(aOR 7.5,95%CI 1.6-35.6)。
临床怎么用
- 作者建议未来医生应更审慎地评估因子VIII剂量和择期手术的依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Research suggests that intensive treatment episodes may increase the risk to develop inhibitors. We performed an international nested case-control study with 298 non-severe hemophilia A patients. Surgery and a high dose of factor VIII concentrate were associated with increased inhibitor risk. Physicians need to review arguments for factor VIII dose and elective surgery extra critically. SUMMARY: Background Inhibitor development is a major complication of treatment with factor VIII concentrates in hemophilia. Findings from studies among severe hemophilia A patients suggest that intensive treatment episodes increase the risk of developing inhibitors. Objectives We set out to assess whether intensive treatment is also associated with an increased risk of inhibitor development among non-severe hemophilia A patients. Patients/Methods We performed a nested case-control study. A total of 75 inhibitor patients (cases) and 223 control patients were selected from 2709 non-severe hemophilia A patients (FVIII:C, 2-40%) of the INSIGHT cohort study. Cases and controls were matched for date of birth and cumulative number of exposure days (EDs) to FVIII concentrates. Conditional logistic regression was used to calculate both unadjusted and adjusted odds ratios (aOR); the latter were adjusted for a priori specified confounders. Results Peak treatment of 5 or 10 consecutive EDs did not increase inhibitor risk (aOR, 1.0; 95% confidence interval (CI), 0.4-2.5; and aOR, 1.8; CI, 0.6-5.5, respectively). Both surgical intervention (aOR, 4.2; CI, 1.7-10.3) and a high mean dose (> 45 IU kg-1 /ED) of FVIII concentrate (aOR, 7.5; CI, 1.6-35.6) were associated with an increased inhibitor risk. Conclusions Our findings suggest that high-dose FVIII treatment and surgery increase the risk of inhibitor development in non-severe hemophilia A. Together with the notion that non-severe hemophilia A patients are at a lifelong risk of inhibitor development, we suggest that in the future physicians will review the arguments for the FVIII dose and elective surgery extra critically.
引用
- van Velzen AS, Eckhardt CL, Peters M, et al. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study. J Thromb Haemost. 2017. PMID: 28440011. doi:10.1111/jth.13711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。